Company: CERO
Filing Date: 2025-05-07
Form Type: DEF 14A
Source: 0001213900-25-040263
Chunk: 20

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-07
Form: DEF 14A
Chunk 20
---
Requirements”). Each of the Bid Price Requirement and MVLS Requirement deficiencies resulted in the commencement of delisting proceedings. However, we attended a hearing before a Nasdaq panel (the “Nasdaq Panel”) on December 17, 2024, at which we submitted a plan to regain compliance with the listing requirements. On January 17, 2025, the Nasdaq Panel granted the Company’s request for an extension of the deadline for regaining compliance with Nasdaq listing requirements to April 22, 2025 (the “Extended Deadline”), subject to certain conditions (the “Nasdaq Conditions”). Pursuant to the Nasdaq Conditions, the Company shall demonstrate compliance with the Bid Price Requirement and apply to transfer its listing to the Nasdaq Capital Market on or prior to January 22, 2025. The Company is also required to satisfy the $2.5 million stockholders’ equity requirement of the Nasdaq Capital Market on or prior to the Extended Deadline, submit certain plans to Nasdaq and make certain disclosures. On April22, 2025, the Company announced that, as a result of the receipt of $2.3million of net proceeds from its equity line of credit entered into November 2024, an additional approximately $4.1million of net proceeds from its public offering of shares of common stock, pre -fundedwarrants and warrants to purchase shares of common stock that closed on February7, 2025 and $5million of investments in marketable securities in consideration for the issuance of Series D Convertible Preferred Stock on April22, 2025, as well as successful negotiations with certain service providers to reduce outstanding balances payable, the Company believes that it has stockholders’ equity of $2.5million requirement as of such announcement and is awaiting a compliance determination from Nasdaq. Until Nasdaq has reached a final determination that the Company has regained compliance with all of the applicable continued listing requirements, there can be no assurances regarding the continued listing of the Company’s common stock and warrants on the Nasdaq Capital Market and the Company could be subject to delisting. On February 12, 2025, we received a letter from the Nasdaq confirming that we had regained compliance with the Bid Price Requirement and we have been moved to the Nasdaq Capital Market, as required by the Nasdaq Panel. However, through April23, 2025, the closing bid price of our Common Stock was below the $1.00 Bid Price Requirement for 26 consecutive trading days before such closing bid price